Jenni Minto, Scottish minister for public health, said the Scottish government was proud to be leading the way in tackling obesity through innovation and collaboration.
“This study places patients and communities at the heart of cutting-edge research into weight-loss medicines, ensuring we build the evidence needed to deliver the greatest benefit to those who need it most,” she said.
UK Science Minister Lord Vallance said: “Scotland has always been at the forefront of medical innovation and public health, and this initiative is further proof of the world-class expertise that can be found here.
“By learning how these weight-loss medicines work, and how we can support them to reach our most deprived areas, we can slash health inequalities in Scotland and the rest of the UK so that our obesity strategy delivers a real, lasting change.”
The study, which will be launched next year, also involves industry leaders Novo Nordisk and IQVIA, as well as clinical leaders at the Universities of Dundee and Edinburgh.
They will work out how to make best use of AI driven digital technologies to support patient access, engagement and data collection.
The study will involve 3,000 to 5,000 Scottish patients living with obesity who will benefit from the medicines the most.